“It is unlikely that B/Yamagata-lineage viruses are circulating in the population. Therefore, it is the opinion of the WHO influenza vaccine composition advisory committee that the inclusion of B/Yamagata-lineage antigens in influenza vaccines is no longer warranted,” the agency said when it released its recommendations for 2024 flu vaccines Sept. 29.
Instead, the WHO is recommending a trivalent vaccine for the 2024 Southern Hemisphere flu season that should target two influenza A viruses — H1N1 and H3N2 — and an influenza B/Victoria virus.
Vaccines for the current flu season in the U.S. still include a Yamagata lineage virus.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
